TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02644317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified shoe inserts
Description: For experimental arm: wear modified shoe inserts and shoes for balance test.
Study: NCT03897556

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Guarana herb
Description: The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Guarana herb
Description: The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
Study: NCT01381068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End tidal CO2 monitor
Description: The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
Study: NCT03523676

Intervention type: DIAGNOSTIC_TEST
Intervention: Red Cell Distribution Width
Study: NCT03897556

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
Study: NCT03641170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Interval walking performed after each main meal.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inactivity
Description: Inactivity after each main meal.

Intervention type: OTHER
Group type: OTHER
Intervention: Fixed diet.
Description: Participants will receive a fixed diet through out the intervention period and control period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed diet.
Description: Participants will receive a fixed diet through out the intervention period and control period.
Study: NCT03407417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual technology - highly tailored
Description: The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual technology - tailored minimally
Description: The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Minimally tailored patient reminders will be customized using 4 randomly selected constructs.
Study: NCT04282668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS1440
Description: Form: Capsule or Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS1440 + ATRA
Description: Form: Capsule or Tablet Route of Administration: Oral
Study: NCT02259426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine combination (Artekin)
Study: NCT01940757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus Hookworm Larvae
Description: Infectious larvae of the human hookworm Necator americanus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus Hookworm Larvae
Description: Infectious larvae of the human hookworm Necator americanus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus Hookworm Larvae
Description: Infectious larvae of the human hookworm Necator americanus
Study: NCT02259426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine combination (Artekin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single-dose 0.25mg/kg
Study: NCT00395317

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablet
Study: NCT03566706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion Tool: Unhealthy Eating
Description: Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion Tool: Marijuana Use
Description: Parent Discussion Tools

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion Tool: Sedentary Behavior
Description: Parent Discussion Tools
Study: NCT01036321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purified isoflavones
Description: Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl cellulose blend
Description: Placebo - Take 2 capsules daily
Study: NCT02598297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: 5 mg tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib Placebo
Description: 5 mg placebo tablet for oral use
Study: NCT04192955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl Salicylate
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetyl Salicylate
Description: Tablets
Study: NCT00935311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712 Extended-release
Description: ABT-712 extended-release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen Immediate-release
Description: Hydrocodone/acetaminophen immediate-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT04979676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Therapy
Description: Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused Therapy
Description: Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Compassion-focused Therapy
Description: Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
Study: NCT03589261

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI (magnetic resonance imaging)
Description: Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
Study: NCT02735668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Conventional Exercises
Description: The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~* Mobilisation Joint Exercises.~* Isometrics and Resisted Exercises (elastic bands).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physiotherapy
Description: The protocol consists in:~* Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~* If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular exercises
Description: The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular exercises
Description: The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Education
Description: The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases.
Study: NCT01053494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage therapy
Description: Undergo massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage therapy
Description: Undergo massage therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention by caregiver
Description: Undergo massage by caregiver

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention by caregiver
Description: Undergo massage by caregiver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Undergo standard follow-up care
Study: NCT02466282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI with bioresorbable vascular scaffold
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography-guided PCI with bioresorbable vascular scaffold
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
Study: NCT03525691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow Extracorporeal CO2 removal
Description: Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow Extracorporeal CO2 removal
Description: Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow Extracorporeal CO2 removal
Description: Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
Study: NCT04407988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate plus Letrozole
Description: pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
Study: NCT03386357

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A (pembrolizumab+RT)
Description: Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B (pembrolizumab)
Description: Pembrolizumab (200mg absolute, q3w)
Study: NCT04590404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.
Description: Automated calls to assess smoking status, medication use, and additional support for quit attempt.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.
Description: Automated calls to assess smoking status, medication use, and additional support for quit attempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: FDA-approved forms of nicotine replacement therapy for smoking cessation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: FDA-approved forms of nicotine replacement therapy for smoking cessation.
Study: NCT00395317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firategrast 150 mg
Description: 150 mg tablet
Study: NCT04590404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: FDA-approved smoking cessation medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation medication.
Study: NCT00395317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firategrast 300 mg
Description: 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firategrast 300 mg
Description: 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firategrast 300 mg
Description: 300 mg tablet
Study: NCT05100277

Intervention type: GENETIC
Intervention: Oncotype DX® Assay
Description: After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.

Intervention type: OTHER
Intervention: Cost
Description: Changes in treatment costs were estimated from Pérola Byington Hospital.
Study: NCT03423004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: the sample will be taken by superficial cutaneous biopsy in psoriasic patients
Study: NCT04186637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-202
Description: Multiple dose levels and dose regimens of ALPN-202 will be administered
Study: NCT01353209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily for twelve months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given daily for twelve months
Study: NCT01934777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid plus Vitamin E plus choline
Description: DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pearls
Description: placebo
Study: NCT03718559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban Monotherapy
Description: Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
Study: NCT02177461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study: NCT03718559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban plus Single Antiplatelet Agent
Description: Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
Study: NCT02939586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemodiafiltration post-dilution model
Description: Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemodialysis
Description: Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
Study: NCT01860833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: time of treatment 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: time of treatment 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: time of treatment 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: time of treatment 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: time of treatment 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: time of treatment 14 days
Study: NCT04031859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
Study: NCT01770574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReproBone
Description: Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: calcaneal lengthening
Description: Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: calcaneal lengthening
Description: Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
Study: NCT01073449

Intervention type: PROCEDURE
Intervention: In-hospital follow-up of cardiac device
Description: Electrical measures taken during normal follow-up and clinical status of the patient
Study: NCT02665182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up-positioning of the testes
Description: Patients in the experimental arm are asked to elevate their testes during the treatment.
Study: NCT02342223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voluma
Study: NCT00662974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal massage with Wheat Germ Oil during the second stage of labor
Description: 30 ml of oil applied during labor
Study: NCT00203164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: rasagiline mesylate 1 mg oral once daily
Study: NCT05336578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin application
Description: PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
Study: NCT03018691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos